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Organ offers in liver transplantation are high-risk medical decisions with a low certainty of whether a better liver offer will
come along before death. We hypothesized that decision support could improve the decision to accept or decline. With data
from the Scientific Registry of Transplant Recipients, survival models were constructed for 42,857 waiting-list patients and
28,653 posttransplant patients from 2002 to 2008. Daily covariate-adjusted survival probabilities from these 2 models were
combined into a 5-year area under the curve to create an individualized prediction of whether an organ offer should be
accepted for a given patient. Among 650,832 organ offers from 2008 to 2013, patient survival was compared by whether
the clinical decision was concordant or discordant with model predictions. The acceptance benefit (AB)—the predicted gain
or loss of life by accepting a given organ versus waiting for the next organ—ranged from 3 to 22 years (harm) and varied
geographically; for example, the average benefit of accepting a donation after cardiac death organ ranged from 0.47 to
20.71 years by donation service area. Among organ offers, even when AB was >1 year, the offer was only accepted 10%
of the time. Patient survival from the time of the organ offer was better if the model recommendations and the clinical deci-
sion were concordant: for offers with AB> 0, the 3-year survival was 80% if the offer was accepted and 66% if it was
declined (P< 0.001). In conclusion, augmenting clinical judgment with decision support may improve patient survival in liver
transplantation. Liver Transpl 21:784-791, 2015. VC 2015 AASLD.
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Liver transplantation is lifesaving for patients with
end-stage liver disease, but it remains limited by the
shortage of high-quality organs. Organ quality can be
classified according to 2 types of donor-specific risks:
(1) the risk of disease transmission, such as malig-
nancy or infection, and (2) the risk of graft failure,
which can vary from 19% to 40% by 3 years according
to the organ received.1
When an organ is offered, the transplant center and
the potential recipient must decide whether to accept
that offer or wait in hopes that a better organ will
come along. These decisions are high-risk ones; a
recent study revealed that 84% of the patients who
die on the waiting list with Model for End-Stage Liver
Disease (MELD) scores15 had previously declined
at least 1 organ offer.2 These decisions are also
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complex ones. Physicians must incorporate multiple
donor factors, recipient factors, and donor-recipient
interactions as well as the local magnitude of the
organ shortage and various technical and logistical
concerns. Thus, it is perhaps not surprising that deci-
sions about organ quality vary widely by transplant
center, suffer from misprediction and cognitive bias,
and are susceptible to external forces such as policy
changes, regulatory scrutiny, and competition
between centers.3-7
Despite the modern era, physicians still evaluate
the tens to hundreds of pieces of data in an organ
offer with mental math and gestalt opinion. We
hypothesize that the availability of a point-of-care
decision aid could improve the consistency and accu-
racy of organ acceptance decisions. Such a tool would
be intended not to replace clinical judgment but
rather to augment it. In fact, the literature on physi-
cian decision support suggests that in many situa-
tions, it is the expert physician whose judgment is
aided the most.8 This article describes the develop-
ment and validation of a tool to predict acceptance
benefit (AB)—the increase or decrease in predicted
survival associated with accepting a given offer for a
given patient versus waiting for the next available
organ.
PATIENTS AND METHODS
Brief Summary
Using data from the Scientific Registry of Transplant
Recipients (SRTR), survival models were constructed
for 42,857 waiting-list patients and 28,653 posttrans-
plant patients from 2002 to 2008. Daily covariate-
adjusted survival probabilities from these 2 models
were combined into a 5-year area under the curve to
calculate AB. Importantly, patients were not censored
at the time of receiving a liver transplant, and this
quantified potential benefits from waiting for a better
organ in some cases.
Model Development
This study used data from the SRTR. The SRTR data
system includes data on all donors, wait-listed candi-
dates, and transplant recipients in the United States
submitted by the members of the Organ Procurement
and Transplantation Network (OPTN), and it has been
described elsewhere. The Health Resources and Serv-
ices Administration of the US Department of Health
and Human Services provides oversight for the activ-
ities of the OPTN and SRTR contractors.
The methodology was adapted from the survival
benefit techniques of Schaubel et al.9 Patients from
the SRTR were included if they were 18 years old
and had received a liver transplant or were on the
waiting list from 2002 to 2008. This time period was
chosen to allow at least 3 years of follow-up for each
patient, with a buffer of at least 1 year from the end
of follow-up in order to maximize the completeness of
the data. Patients listed as status 1 or with MELD
exceptions other than hepatocellular carcinoma (HCC)
were excluded in order to minimize heterogeneity in
the subject population. Notably, a sensitivity analysis
including these patients was also performed, and the
results were not significantly changed, as reported
later.
A Cox regression was used to create 2 separate
models, (1) the waiting-list model and (2) the post-
transplant model, with the Breslow method to esti-
mate the baseline hazard function. The waiting-list
model was created with 10 cross-sections of the wait-
ing list at 8-month intervals during the study period.
The outcome was death, and patients were censored
upon the end of follow-up or the receipt of a living
donor transplant. However, patients were not cen-
sored for any other reason, such as removal from the
waiting list or receipt of a deceased donor transplant.
This key difference from a traditional survival-benefit
analysis permitted the model to account for what
would happen if a given offer was declined and the
patient was then later transplanted with a different
organ. The posttransplant model began at the time of
transplant and ended with death or the end of the
follow-up period. In both models, a time horizon of 5
years was used.
Recipient covariates included the following: most
recently assigned MELD score (match MELD score),
recipient age, serum creatinine, serum bilirubin,
serum international normalized ratio (INR), serum
sodium, serum albumin, body mass index (BMI), dial-
ysis, diabetes, chronic obstructive pulmonary disease
(COPD), portal vein thrombosis, HCC, hepatitis C
virus (HCV), prior abdominal surgery, prior liver
transplant, prior nonliver transplant, prior malig-
nancy, blood type, and percentage of time inactive on
the waiting list (waiting-list model only). Donor covari-
ates (posttransplant model only) included donor age,
donation after cardiac death (DCD), donor cause of
death [anoxia, cerebrovascular accident (CVA), and
other], donor height, donor weight, history of malig-
nancy, hepatitis C, split liver, regional or national
share, and cold ischemia time (CIT). Notably, because
CIT is not available at the time of the organ offer and
must be estimated, we performed a sensitivity analy-
sis by comparing the results with CIT excluded. Other
covariates included the donation service area (DSA)
and the interaction between donor age and recipient
HCV status. Other interactions, such as the interac-
tion between donor and recipient height and weight,
were not significant in a bivariate analysis and were
thus excluded from the final model. Candidates and
recipients who were missing data on creatinine, biliru-
bin, INR, or albumin at the time of the cross-section
or transplant were excluded from the analysis [919
candidates (2%) and 8 recipients (<0.01%)]. Data for
creatinine, bilirubin, INR, and albumin were log-
transformed and centered; values for age and CIT
were centered before entry in the models. Indicator
variables were created and included in the models for
missing values for each of the following covariates:
BMI (<1.5% missing), sodium (38%), and CIT (9%).
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The percentage of missing serum sodium values was
high because collection of this data field did not begin
until 2004. All other variables had a very low rate of
missing data and/or a low proportion of positive val-
ues; any misclassification bias caused by this should
have biased the parameter estimates toward the null.
Subject-specific daily survival probabilities from the
covariate-adjusted Cox models were combined into a
5-year area under the survival curve. The benefit (in
years) of accepting a given organ versus staying on
the waiting list with the possibility of a future trans-
plant was calculated as follows: the posttransplant
area minus the waiting-list area equals AB. This can
be described in mathematical terms as follows.
The survival probability at a given time (t) for a given
patient (i) after transplantation with a given organ (x)
can be expressed as
STX ;i;qðtÞ5STX ;0;oðtÞe
b1X11b2X21...1bqXq
where STX,i,q(t) is the posttransplant survival probabil-
ity at time t for patient i and organ q. STX,0,o(t) is the
baseline posttransplant survival probability at time t
(for the average patient and organ). b1, b2, . . . bp are
the coefficients for variables in the posttransplant
model described. The cumulative survival probability
TXi,q can be calculated for that same patient and
reflects the sum of the daily survival probabilities,
STX,i,q(t), for the study period (5-year area under the
survival curve):
TXi;q5
X1095
t51
STX ;i;qðtÞ
Similarly, the survival measure WLi can be calcu-
lated for that same patient if he or she were to turn
down the organ offer with the daily survival probabil-
ity, SWL,i(t), based on the waiting-list model.
Finally, the survival benefit of a given patient
accepting a given organ rather than waiting for
another to come along is calculated as
ABi;q5TXi;q–WLi
This number, which can range from 25 to 5, reflects
the additional number of extra (or fewer) years a given
patient would be expected to live with that particular
organ versus remaining on the waiting list with the
possibility of future transplantation. A positive num-
ber suggests that the organ offer should be accepted,
whereas a negative number suggests that it should be
declined.
Postestimation was then used to calculate predicted
AB values for various recipient-donor combinations.
Determining the degree of uncertainty in model pre-
dictions proved difficult because no established meth-
ods exist to express confidence intervals in a survival-
benefit analysis. We, therefore, estimated the best-
case scenario for AB by calculating the 25th percen-
tile of estimated survival for the waiting-list model
and the 75th percentile of estimated survival for the
posttransplant model (and vice versa for the worst-
case scenario). Recipient-donor combinations with
nondiscrepant best-case/worst-case combinations
(AB, both 0 and 0) were determined to be high-
certainty predictions. We also chose 0.5 years as an a
priori cutoff for significant benefit or harm because
this is a clinically meaningful interval during which
some patients may lose their window for transplanta-
tion. Finally, the independent contribution of each of
the recipient and donor characteristics was assessed
with linear regression with predicted AB as the
dependent variable.
Model Validation
Several types of model validity, including concurrent,
construct, criterion, and predictive validity, were
assessed. Concurrent validity was assessed through
the comparison of model predictions with those calcu-
lated by another statistical method—in this case,
sequential stratification. An offshoot of Cox regres-
sion, sequential stratification can be used to compare
the relative risk of patient mortality associated with
transplant while accounting for time-dependent
patient characteristics.10 With the same waiting-list
cohort cited previously, patients who received a trans-
plant were matched to subjects on the waiting list
that day who did not receive a transplant but who
had the same laboratory MELD score, were in the
same DSA, and had been listed for the same amount
of time. The cohort was then divided by MELD and
donor risk index (DRI) quartiles, and this yielded 16
subgroups that were fitted by separate Cox regres-
sions. The hazard ratio in each subgroup represents
the relative risk associated with transplantation for a
candidate in that MELD group receiving an organ in
that DRI group. The hazard ratios from the sequential
stratification for each subgroup were then compared
with the AB scores from this cohort with linear regres-
sion. Notably, sequential stratification was not used
for the primary analysis because the ultimate goal of
this project is to create a point-of-care decision sup-
port tool, and the output from sequential stratification
(hazard ratio) is not easily interpreted by patients or
physicians.
Construct validity was assessed by the calculation
of AB at various MELD score and DRI levels; we
anticipated that AB would increase with an increasing
MELD score and would decrease with an increasing
DRI. We also analyzed AB by DSA and hypothesized
that AB would vary on the basis of the local severity
of the organ shortage. The criterion validity was
assessed with match-run data from 2008 to 2013; we
excluded offers labeled “B” for bypass and offers of
organs that were not eventually used for transplanta-
tion. These offers were restricted to the top patient in
each match run and thus did not include provisional
offers or candidates lower on the list than the one
who eventually accepted the organ. Among the 26,792
accepted offers, 26,045 patients (97.2%) underwent
transplantation with that organ. We expected that
with increasing AB, a higher proportion of offers
would be accepted; thus, the criterion was the expert
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opinion of the transplant surgeon in each case. Pre-
dictive validity was assessed by an analysis of the
patient survival after the organ offer according to
whether the model predicted a positive or negative AB
and whether or not the offer was accepted.
This study was approved by our institutional review
board.
RESULTS
The waiting-list model included 117,741 observations
among 42,857 individual patients, and it resulted in a
C-statistic of 0.67 for predicting survival. The post-
transplant model included 28,653 patients, and it
resulted in a C-statistic of 0.63 for predicting survival.
Among the patients in the waiting-list model who
received a deceased donor liver transplant, there was
a strong correlation between AB scores and hazard
ratios from sequential stratification (r250.90), and
this indicated good concurrent validity of the model. A
sensitivity analysis, which was performed by the
inclusion of patients with non-HCC exceptions and
status 1 patients and by the exclusion of CIT, demon-
strated a strong correlation with the original results
(Pearson correlation coefficients of 0.997 and 0.992,
respectively).
As expected, median AB scores were higher among
patients with higher MELD scores and were lower
with organs having higher DRI scores, as shown in
Fig. 1. The predicted benefit also varied by geographic
location. For example, as shown in Fig. 2, for an aver-
age 54-year-old man with alcoholic cirrhosis and a
MELD score of 22 being offered a DCD liver, the AB
ranged from 20.71 to 0.47 years according to the
DSA.
The independent contributions of various donor and
recipient characteristics to AB are shown in Table 1
with adjustments for DSA. A positive coefficient
means having that characteristic is associated with
an increased likelihood of benefit from accepting a
given organ offer rather than waiting for another offer
to come along. For example, after adjustments for lab-
oratory measures of the severity of liver disease (creat-
inine, bilirubin, and INR), a higher match MELD score
Figure 1. AB by laboratory MELD score and DRI. The box indicates the interquartile range, with the horizontal line at the median, the
diamond at the mean, and the whiskers indicating values that are 1.5 times the interquartile range.
LIVER TRANSPLANTATION, Vol. 21, No. 6, 2015 VOLK ET AL. 787
was associated with lower AB because those patients
are more likely to receive additional offers in the near
future. Conversely, older age was associated with
higher AB, possibly because older patients tend to
have a more rapid decline in their functional status.
Several case examples are provided in Table 2.
Among organ offers from 2008 to 2013 that were
eventually used for transplantation, the distribution
of AB scores is shown in Fig. 3. A large proportion of
offers had a predicted AB clustered near zero, and
this highlights the difficulty in making these clinical
decisions. However, 23% and 8% had an AB>0.5 and
an AB <–0.5, respectively, and this indicated a signifi-
cant predicted benefit or harm from accepting that
offer for that patient. Furthermore, in 44% of the
offers, the best-case and worst-case AB probabilities
were both either 0 or 0, and this indicated a high
degree of certainty for the model prediction among
those cases.
The proportion of offers that were actually accepted
is shown in Table 3. There was a clear increase in the
acceptance rate with increasing AB, and this sup-
ported the criterion validity of the model; however, it
is interesting that even among organs eventually used
for transplant, 90% of the offers were declined despite
a predicted AB>1 year. As shown in Fig. 4, if the pre-
dicted AB was <0 (the model predicted that the
patient would be better off waiting), the actual patient
survival from the time of the organ offer was margin-
ally better if the offer was declined rather than
accepted. Conversely, if the predicted AB was >0, the
actual patient survival was substantially better if the
offer was accepted rather than declined (3-year sur-
vival, 80% versus 66%; P<0.001).
DISCUSSION
This study aimed to develop and validate the statisti-
cal methodology for a decision support tool for organ
offers in liver transplantation. Our model demon-
strated strong concurrent, construct, criterion, and
predictive validity. Most importantly, patient survival
was better if the model suggestion to accept or decline
was followed in actual practice. This finding suggests
that the use of this decision support tool at the time
of the organ offer might improve overall outcomes in
the liver transplant population. The next step will be
to test this concept in real-world clinical practice.
It is striking that among organ offers with a pre-
dicted AB>1 year, 90% were declined; it is particu-
larly striking because patients with a positive AB had
an improved 3-year survival of 80% if the organ was
accepted versus 66% if the organ was declined. This
finding might be explained by unmeasured covariates
such as sarcopenia and infection11; in other words,
perhaps the clinical decision was the correct decision,
Figure 2. Predicted benefit of accepting a DCD liver for a 54-year-old man with a match MELD score of 22 by DSA.
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TABLE 1. Multivariate Model Demonstrating the Impact of Recipient and Donor Factors on AB
Variable Parameter Estimate Pr>|t|
Match MELD
11-15 (versus <11) 20.0194 0.0005
16-20 (versus <11) 20.0988 <0.0001
21-25 (versus <11) 20.1603 <0.0001
26-30 (versus <11) 20.1578 <0.0001
31-40 (versus <11) 20.3368 <0.0001
Age at transplant (per year) 0.0196 <0.001
loge creatinine 0.1325 <0.0001
loge albumin 21.1687 <0.0001
loge INR 0.0198 <0.0001
loge bilirubin 0.1948 <0.0001
Sodium, mEq/L
Sodium missing 20.2015 <0.0001
Sodium<130 (versus 134 sodium<139) 0.3762 <0.0001
130 sodium<134 (versus 134 sodium<139) 0.1310 <0.0001
139 sodium<131 (versus 134 sodium<139) 20.1315 <0.0001
141 sodium (versus 134 sodium<139) 20.1276 <.0001
BMI, kg/m2
BMI missing 20.0046 0.67
BMI<20 (versus 20BMI<25) 0.0832 <0.0001
25BMI<30 (versus 20BMI<25) 0.0096 <0.0001
30BMI<35 (versus 20BMI<25) 0.0669 <0.0001
35BMI (versus 20BMI<25) 0.1971 <0.0001
Dialysis 20.0023 0.52
Diabetes 0.0978 <0.0001
0%< Inactive %10% (versus 0%) 0.1519 <0.0001
10%< Inactive %40% (versus 0%) 0.1094 <0.0001
40%< Inactive % (versus 0%) 0.0234 <0.0001
COPD 0.2201 <0.0001
Portal vein thrombosis 20.2090 <0.0001
HCC 20.0323 <0.0001
HCV 20.0920 <0.0001
Previous abdominal surgery 20.0152 <0.0001
Previous liver transplant 20.2690 <0.0001
Previous nonliver transplant 20.5363 <0.0001
Previous malignancy 20.0249 <0.0001
Blood type
A (versus O) 20.0121 <0.0001
B (versus O) 20.1578 <0.0001
AB (versus O) 20.2320 <0.0001
Donor age (per year) 20.0046 <0.0001
DCD donor 20.29312 <0.0001
Donor cause of death
Anoxia (versus trauma) 20.0030 0.27
CVA (versus trauma) 20.0509 <0.0001
Donor height (cm) 0.0026 <0.0001
Donor weight (kg) 0.0002 0.0003
Donor race
African American (versus white) 0.0045 0.07
Hispanic (versus white) 20.1260 <0.0001
Other (versus white) 20.1985 <0.0001
Split liver transplant 20.2322 <0.0001
Regional share transplant (versus local) 20.06454 <0.0001
National share transplant (versus local) 20.1152 <0.0001
Donor anti-HCV positive 20.0840 <0.0001
Donor history of cancer 20.1046 <0.0001
CIT centered at 8 hours 20.0107 <0.0001
Missing CIT 20.2149 <0.0001
Interaction: HCV 3 donor age 20.0106 <0.0001
NOTE: A positive coefficient means that the variable is associated with an increased likelihood of benefit from accepting a
given organ (vice versa for a negative coefficient).
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and the patient would in reality have done poorly
even with transplantation. However, this possibility
seems unlikely to be the sole explanation; in our clini-
cal experience, fewer than 1 in 5 patients on the wait-
ing list are frail and marginal.12 Unmeasured donor
characteristics are also unlikely to account for all
declined offers because each of these organs was
eventually used for transplantation. Most importantly,
the converse was also true: patients with a negative
AB had better survival if the organ was declined
rather than accepted. An alternate explanation is that
these offers represent missed opportunities for suc-
cessful transplantation because of well-intended
errors in decision making.13 The decision to decline
may also be related to regulatory or financial consid-
erations; recent evidence has pointed to risk aversion
as an unintended consequence of regulatory over-
sight.6 Ultimately, a prospective study will be the only
way to know for sure which explanation is the correct
one and whether the decision tool would improve
decision making in actual practice.
Although a strength of this study lies in the use of
the SRTR database to allow for the analysis of the
entire national experience with liver transplantation,
a limitation is the database’s lack of granularity, par-
ticularly with respect to additional information such
as donor liver biopsy results, donor laboratory trends,
donor hemodynamic stability, and other factors that
TABLE 2. Examples of Donor-Recipient Combinations and the Associated AB
Recipient Donor AB (Years)
55 years old, laboratory MELD 9,
HCC exception, otherwise good candidate
50-year-old brain-dead donor,
expected CIT 6 hours
0.11
55 years old, laboratory MELD 22
(bilirubin 7, INR 2, creatinine 1),
otherwise good candidate
50-year-old brain-dead donor,
expected CIT 6 hours
0.35
55 years old, laboratory MELD 9,
HCC exception, otherwise good candidate
50-year-old cardiac death donor,
expected CIT 6 hours
20.15 (harm)
55 years old, laboratory MELD 22
(bilirubin 7, INR 2, creatinine 1),
otherwise good candidate
50-year-old cardiac death donor,
expected CIT 6 hours
0.14
NOTE: All examples are in the Michigan organ procurement organization.
Figure 3. Distribution of AB scores among liver offers from
2008 to 2013 (restricted to offers of organs that were eventually
used for transplantation).
TABLE 3. Proportion of Liver Offers Accepted by AB
Score (Restricted to Offers of Organs That Were
Eventually Used for Transplantation)
AB (years)
Number
of Offers
Accepted
(%)
Overall 650,832 4.1
<–0.5 (harm) 54,466 1.5
20.5 to 20.25 (harm) 79,096 2.1
20.25 to 0 (harm) 136,157 2.5
0 to 0.25 132,387 3.6
0.25 to 0.5 98,858 4.7
0.5 to 1 103,596 6.5
>1 46,272 10.2
Figure 4. Patient survival from the time of organ offer by pre-
dicted AB (>0 versus <0) and by whether or not the liver was
actually accepted.
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surgeons may use to make decisions about the suit-
ability of a given organ for a given recipient. This lack
of granularity makes it difficult to understand the
context in which the organ offer decisions were made.
For example, in many situations, an offer may be
declined for one patient because of plans to later
accept it for another patient; it is difficult to piece
together such scenarios with large databases. Another
limitation of the study was the relatively modest pre-
dictive ability of the statistical model. Although it is
difficult with this methodology to generate confidence
intervals around each predicted AB, one can assume
reasonable confidence in the direction of the model
prediction in 44% of organ offers, as evidenced by
concordance between best-case and worst-case esti-
mates. Furthermore, it is reassuring that the results
appeared very similar when a different statistical
method (sequential stratification) was used. A third
important limitation with respect to future implemen-
tation in clinical practice is that organ allocation pol-
icy changes over time. For example, in the past 10
years, there have been changes in priority for patients
with HCC as well as regional sharing rules for
patients with MELD scores>15 and>35. This means
that the model would need to be updated periodically
in order to reflect current reality. However, despite
these policy changes, the model (which was developed
from 2002-2008 data) seemed to outperform clinical
judgment in the time period from 2008 to 2013.
Finally, the model endpoint is survival, which has the
advantage of being objective, but it does not account
for important subjective endpoints such as quality of
life.
In summary, our findings support the proof of con-
cept that decision support may be a useful adjunct to
clinical judgment when organ offers are being consid-
ered. We emphasize that this tool is never intended to
replace clinical judgment. Furthermore, this was a
retrospective study, and this tool is not yet ready for
routine clinical practice. In addition to further model
improvement, the next step will be to study this sup-
port tool prospectively in order to determine its effec-
tiveness and feasibility. To this end, we have
converted the tool into a web-based interface, which
can be seen at https://dev.ltorganoffer.org/demo/
index/ (the username and the password are user and
demo, respectively). We welcome feedback from the
transplant community about improvements for the
next iteration, which will include information about
potential regulatory impacts from the decision as well
as other considerations.
REFERENCES
1. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM,
Punch JD, DebRoy MA, et al. Characteristics associated
with liver graft failure: the concept of a donor risk index.
Am J Transplant 2006;6:783-790.
2. Lai JC, Feng S, Roberts JP. An examination of liver offers
to candidates on the liver transplant wait-list. Gastroen-
terology 2012;143:1261-1265.
3. Volk ML, Reichert HA, Lok AS, Hayward RA. Variation in
organ quality between liver transplant centers. Am J
Transplant 2011;11:958-964.
4. Volk ML, Roney M, Merion RM. Systematic bias in sur-
geons’ predictions of the donor-specific risk of liver trans-
plant graft failure. Liver Transpl 2013;19:987-990.
5. Volk ML, Lok AS, Pelletier SJ, Ubel PA, Hayward RA.
Impact of the Model for End-Stage Liver Disease alloca-
tion policy on the use of high-risk organs for liver trans-
plantation. Gastroenterology 2008;135:1568-1574.
6. Skaro AI, Wang E, Lyksemburg V, Ladner D, Jay CL,
Chang Y, et al. Risk aversion in liver transplantation: the
dark side of quality improvement and regulatory over-
sight. J Surg Res 2011;165:260.
7. Halldorson JB, Paarsch HJ, Dodge JL, Segre AM, Lai J,
Roberts JP. Center competition and outcomes following
liver transplantation. Liver Transpl 2013;19:96-104.
8. Brailer DJ, Kroch E, Pauly MV. The impact of computer-
assisted test interpretation on physician decision mak-
ing: the case of electrocardiograms. Med Decis Making
1997;17:80-86.
9. Schaubel DE, Guidinger MK, Biggins SW, Kalbfleisch JD,
Pomfret EA, Sharma P, Merion RM. Survival benefit-
based deceased-donor liver allocation. Am J Transplant
2009;9(pt 2):970-981.
10. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion
RM. The survival benefit of deceased donor liver trans-
plantation as a function of candidate disease severity
and donor quality. Am J Transplant 2008;8:419-425.
11. Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE,
Harbaugh C, et al. Sarcopenia and mortality after liver
transplantation. J Am Coll Surg 2010;211:271-278.
12. Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H,
Covinsky K. Frailty predicts wait-list mortality in liver
transplant candidates. Am J Transplant 2014;14:1870-
1879.
13. Volk ML, Berg CL. Declined organ offers in liver trans-
plantation: careful timing or missed opportunity? Gastro-
enterology 2012;143:1141-1143.
LIVER TRANSPLANTATION, Vol. 21, No. 6, 2015 VOLK ET AL. 791
